1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Cellbxhealth PLC

Cellbxhealth PLC

ANPCF
Cellbxhealth PLCUS flagOther OTC
0.02
USD
- -
- -
6.53MMarket Cap
Cellbxhealth PLC
ANPCF
(Other OTC)

Recent

price

0.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.09
0.08
0.04
0.02
0.02
- -
0.01
0.01
0.01
- -
- -
- -
- -
0.01
0.01
- -
Revenue per Share
- -
-0.01
-0.08
-0.02
-0.02
-0.08
-0.08
-0.09
-0.08
-0.07
-0.07
-0.07
-0.09
-0.08
-0.05
-0.06
Basic EPS, GAAP
-0.03
-0.03
-0.03
-0.06
-0.05
-0.08
-0.09
-0.11
-0.09
-0.06
-0.05
-0.07
-0.07
-0.06
-0.05
-0.03
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.48
-0.43
-0.41
-0.35
-0.34
-0.36
-0.38
-0.37
-0.32
-0.26
-0.27
-0.27
-0.31
-0.37
-0.34
-0.34
Book Value per Share
0.15
0.14
0.12
0.14
0.1
0.19
0.07
0.09
0.11
0.09
0.17
0.16
0.15
0.08
0.05
0.02
Tangible Book Value per Share
27
29
34
41
45
48
59
73
96
137
178
225
247
260
295
354
Basic Weighted Avg Shares
2
2
1
1
1
- -
- -
- -
1
1
1
1
1
2
3
1
Sales/Revenue/Turnover
4.07
-3.1
-97.53
-133.95
-276.03
- -
-1,509.42
-1,482.93
-1,424.52
-1,593.22
-1,711.55
-1,710.46
-2,508.07
-935.86
-540.74
-1,140.04
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
1
3
2
2
6
Depreciation Expense
- -
- -
-3
-1
-1
-4
-5
-7
-8
-9
-12
-15
-22
-20
-14
-20
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-1.83
-14.63
-183.73
-89.37
-132.83
- -
-1,355.4
-1,318.67
-1,203.18
-1,318.88
-1,523.1
-1,481.93
-2,083.19
-920.95
-497.03
-1,444.04
Profit Margin (%)
- -
- -
1
3
4
9
3
6
9
11
29
34
33
17
13
7
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
2
4
4
3
1
LT Debt
4
5
4
7
6
10
5
9
16
17
34
40
40
23
18
7
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.5%
-21.31%
-60.98%
Free Cash Flow
13.97%
9.46%
-31.53%
Net Income, GAAP
20.8%
14.89%
37.15%
Sales/Revenue/Turnover
- -
24.76%
-52.8%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
2
2024
- -
- -
- -
- -
3
2025
- -
- -
- -
- -
1

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.08
2024
- -
- -
- -
- -
-0.05
2025
- -
- -
- -
- -
-0.06

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Precision System Science Co., Ltd. (7707.T)
Medpace Holdings, Inc. (MEDP)
Amoy Diagnostics Co., Ltd. (300685.SZ)
Exact Sciences Corporation (EXAS)
ENDRA Life Sciences Inc. (NDRA)
Qiagen N.V. (QGEN)
Business
Cellbxhealth PLC (ticker: ANPCF), formerly Angle PLC, is a medical diagnostics company founded in 2003 and headquartered at 10 Nugent Road, Surrey Research Park, Guildford, United Kingdom, that specializes in liquid biopsy solutions for cancer research, drug development, and clinical applications through its patented Parsortix technology. The Parsortix PC1 system, the first FDA-cleared medical device for capturing and harvesting intact circulating tumor cells (CTCs) and CTC clusters from whole blood of metastatic breast cancer patients using microfluidic cassettes in an automated platform, enables downstream user-validated analysis including enumeration of epithelial and mesenchymal CTC populations; the company also offers Portrait+ CTC Staining kit for high-sensitivity identification and characterization of epithelial and mesenchymal transition CTCs, Portrait Flex immunofluorescence assays for epithelial-to-mesenchymal transition, DNA damage response, and PD-L1 evaluation, CellKeep Slide for CTC harvesting, and custom CTC assays, alongside GCP-compliant laboratory services from its GCLP-certified UK facility providing global CTC harvesting, bespoke clinical-trial support, assay development, and co-development of laboratory-developed tests for biopharmaceutical and translational research partners. Cellbxhealth operates primarily in Europe and North America, targeting clinical laboratories, pharmaceutical companies, and researchers with a focus on precision oncology via non-invasive CTC intelligence that complements tissue and circulating tumor DNA-based tests. In November 2025, the company announced a £6.8 million fundraising through a placing of up to 493 million shares, subscription for 187 million shares, and retail offer at 1.0 pence per share to support a strategic shift from research-focused operations to a commercially-driven model emphasizing product sales via clinical lab partnerships, laboratory services for pharma partners, and LDT co-development, following CEO Andrew Newland and Finance Director Ian Griffiths' resignations in September 2025; leadership under Executive Chairman Dr. Jan Groen and interim CEO Peter Collins is advancing collaborations with QIAGEN, Roche Diagnostics, Myriad Genetics, and Illumina for CTC workflow validation, alongside a 60% headcount reduction by year-end 2025 to cut annual costs by over £5.9 million, with plans for EBITA positivity by end-2028 and a £12.6 million qualified pipeline.

Company News

APIChatGPT